Skip to main content
. 2020 Jan 3;99(1):e18462. doi: 10.1097/MD.0000000000018462

Figure 2.

Figure 2

The relationship between the serum levels of IL-26 and alanine aminotransferase (ALT)/aspartate aminotransferase (AST). (A and B) CHB patients were divided into 2 groups based on the serum ALT or AST levels. The serum IL-26 levels were measured and compared. (C and D) The serum ALT and AST levels were measured in CHB patients at weeks 0 (baseline), 12, 24, 36, and 52 post LdT therapy. Data are expressed as mean ± SD. ∗P < .05, ∗∗P < .01; n = 30. ALT, alanine aminotransferase; AST, aspartate aminotransferase; IL-26, interleukin-26.